© Reuters.
NEW YORK – AbCellera Biologics Inc (NASDAQ:ABCL), a biotechnology firm, saw its shares drop by 7.24%, closing at $5.39. Despite this decline, the company maintains a solid market presence with a market capitalization of $1.45 billion and roughly 290,170K shares in circulation.
Analysts have adjusted their expectations for the company’s financial performance, predicting a significant earnings per share (EPS) drop to -191.96% for this fiscal year. However, there is a positive outlook for the next fiscal year, with EPS projected to rebound to $5.
Institutional investors such as Baillie Gifford and Baker Brothers Advisors remain major stakeholders in AbCellera, reflecting continued confidence from large financial entities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.